Urothelial carcinoma

Researchers test whether four cycles of dose-dense MVAC chemotherapy, given with G-CSF support, can shrink or eliminate muscle-invasive bladder cancer before radical surgery. The trial enrolls 24 adults with locally advanced urothelial carcinoma of the bladder who are fit for cis…

This early-phase trial tested enfortumab vedotin, a drug placed directly into the bladder via a catheter, in 37 people with a type of bladder cancer that did not respond to standard BCG therapy. The main goals were to check safety and side effects, and to see if the drug could he…

This trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…

This early-stage trial tests a new type of immunotherapy called 4SCAR-T cells in 20 people with advanced bladder cancer that has spread and no longer responds to standard treatments. The cells are genetically modified to recognize and attack cancer cells. The study aims to see if…

This trial investigates a combination of two drugs: EP0057, a chemotherapy drug wrapped in a nanoparticle to help it reach cancer cells, and olaparib, which stops cancer cells from fixing DNA damage. The study includes adults with small cell lung cancer, bladder cancer, or prosta…

This study tested several immunotherapy-based drug combinations in 272 people with advanced bladder cancer that had worsened after platinum chemotherapy. The goal was to see which combinations were safest and most effective at shrinking tumors or slowing the disease. Participants…

This trial tests whether an experimental drug called XNW5004, which blocks a protein that helps cancer grow, can boost the effects of the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have stopped responding to standard treatments. The study inc…

This trial is testing an experimental drug called NUC-3373, a nucleotide analogue, in combination with standard cancer drugs for people with advanced solid tumors. The study has two parts: one combining NUC-3373 with pembrolizumab, and the other combining it with docetaxel. The g…

This early-phase trial tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, breast, lung, and other cancers. The study aimed to check safety and see if the drug could shrink tumors. However, the trial was terminated early, so f…

This early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…

This early-phase study tested a combination of two drugs—atezolizumab (an immunotherapy) and epacadostat (an oral drug that helps the immune system attack cancer)—in 29 patients with advanced lung or bladder cancer that had already been treated with chemotherapy. The main goal wa…

This early-stage trial tested an experimental drug called AUR106 in 21 adults with advanced solid tumors (lung, stomach, bladder, kidney, colon, or esophageal cancer) that had come back or spread. The main goals were to check safety, find the right dose, and see how the drug move…

This early-phase trial tested a new drug called BAT8007 in 93 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target a protein called Nectin-4 on cancer cells and deliver a chemotherapy agent directly to them. The main…

This early study tested adding a testosterone-lowering drug (degarelix) to standard chemotherapy for people with muscle-invasive bladder cancer that has testosterone receptors. Only 2 people enrolled before the study was stopped. The goal was to see if the combination could elimi…

This study tested an experimental drug called enfortumab vedotin, alone or with other cancer drugs, in people with advanced bladder or urinary tract cancer. The goal was to see if the drug could shrink tumors and control the disease. The trial included 348 participants but was te…

This early-stage study tested an experimental oral drug (PF-07265028) alone or combined with an immunotherapy injection (sasanlimab) in 21 people with advanced solid tumors, including stomach, lung, and head/neck cancers. The main goals were to find a safe dose and check for side…

This study tested a combination of two drugs, selinexor and pembrolizumab, in people with advanced bladder cancer who either couldn't take the standard chemo drug cisplatin or whose cancer got worse after cisplatin. The goal was to find the best dose and see if the combo could sh…

This early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…

This study tested a combination of two drugs, futibatinib and pembrolizumab, in 43 people with advanced or metastatic bladder cancer who could not receive standard chemotherapy. The goal was to see if the combo could shrink tumors and to check its safety. The trial was terminated…

This study looked at whether adding an immunotherapy drug (pembrolizumab) to a targeted therapy (pemigatinib) works better than the targeted therapy alone or standard care for people with advanced bladder cancer that has a specific gene change (FGFR3). The study was stopped early…

This phase 2 study tested several drug combinations (retifanlimab, epacadostat, INCAGN02385, INCAGN02390) given before bladder removal surgery in 30 patients with muscle-invasive bladder cancer who could not take the standard chemo drug cisplatin. The trial was terminated early, …

This study tested a combination of three drugs (azacitidine, pembrolizumab, and epacadostat) in 70 people with advanced solid tumors, including lung and colorectal cancers. The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminated …

This early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so result…

This phase 2 trial tested whether adding trilaciclib (Cosela) to standard chemotherapy and avelumab could help people with advanced bladder cancer by protecting their bone marrow. The study enrolled 92 adults with untreated, locally advanced or metastatic urothelial carcinoma. Un…